Maralixibat + Placebo
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Familial Intrahepatic Cholestasis (PFIC)
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Trial Timeline
Oct 25, 2018 → Jun 15, 2020
NCT ID
NCT03353454About Maralixibat + Placebo
Maralixibat + Placebo is a phase 3 stage product being developed by Mirum Pharmaceuticals for Progressive Familial Intrahepatic Cholestasis (PFIC). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03353454. Target conditions include Progressive Familial Intrahepatic Cholestasis (PFIC).
What happened to similar drugs?
2 of 20 similar drugs in Progressive Familial Intrahepatic Cholestasis (PFIC) were approved
Approved (2) Terminated (4) Active (14)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03353454 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Progressive Familial Intrahepatic Cholestasis (PFIC)